Literature DB >> 36029306

Orbital solitary fibrous tumours: clinicopathological characteristics and recurrence prediction.

Xiao-Jin Gao1,2, Xiao-Lin Peng1, Yu-Jiao Wang1, Wei-Min He3.   

Abstract

BACKGROUND: SFTs are thought to have an unpredictable clinical course and currently have no recognized prognostic criterion. Our study aimed to determine the relationship between clinicopathological characteristics and the prognosis of patients with orbital SFTs.
METHODS: The clinicopathological features of these patients were extracted from clinical records. The relationships between these features and prognosis were analysed.
RESULTS: The positive rates of CD34, CD99, Blc2, and STAT6 expression were 90.3%, 90.3%, 83.9%, and 100%, respectively. The tumour recurrence rate was 38.7%. A higher recurrence rate was observed in patients with Ki67 index ≥ 5 (56.25% vs. 20%, P = 0.038).
CONCLUSION: A Ki67 index ≥ 5 was an effective parameter for predicting tumour recurrence of orbital SFTs. Close follow-up is needed for these patients.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Clinicopathological characteristics; Ki67; Orbit; Recurrence prediction; Solitary fibrous tumour

Year:  2022        PMID: 36029306     DOI: 10.1007/s00417-022-05795-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.535


  22 in total

1.  Primary neoplasms of the pleura. A report of five cases.

Authors:  P Klemperer; B R Coleman
Journal:  Am J Ind Med       Date:  1992       Impact factor: 2.214

2.  Orbit Solitary Fibrous Tumor: A Proposed Risk Prediction Model Based on a Case Series and Comprehensive Literature Review.

Authors:  Lester D R Thompson; Sofia S Liou; Kenneth A Feldman
Journal:  Head Neck Pathol       Date:  2020-06-11

Review 3.  Solitary fibrous tumour--everywhere, and a diagnosis in vogue.

Authors:  J K Chan
Journal:  Histopathology       Date:  1997-12       Impact factor: 5.087

4.  Clinicopathological and genetic heterogeneity of the head and neck solitary fibrous tumours: a comparative histological, immunohistochemical and molecular study of 36 cases.

Authors:  Yu-Chien Kao; Po-Chun Lin; Shao-Lun Yen; Shih-Chiang Huang; Jen-Wei Tsai; Chien-Feng Li; Hui-Chun Tai; Jui Lan; I-Chieh Chuang; Shih-Chen Yu; Hsuan-Ying Huang
Journal:  Histopathology       Date:  2015-08-17       Impact factor: 5.087

Review 5.  Dedifferentiated Solitary Fibrous Tumor: A Concise Review.

Authors:  Nicholas J Olson; Konstantinos Linos
Journal:  Arch Pathol Lab Med       Date:  2018-06       Impact factor: 5.534

6.  Clinicopathologic and immunohistochemical features of five new cases of solitary fibrous tumor of the oral cavity.

Authors:  Román Carlos; Bruno Augusto Benevenuto de Andrade; Nathalie Henriques Silva Canedo; Aline Corrêa Abrahão; Michelle Agostini; Oslei Paes de Almeida; Mário José Romañach
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2015-11-14

7.  Papillary Solitary Fibrous Tumor/Hemangiopericytoma: An Uncommon Morphological Form With NAB2-STAT6 Gene Fusion.

Authors:  Zhi-Gang Yao; Hai-Bo Wu; Ying-Hua Hao; Xing-Fu Wang; Guang-Zhen Ma; Jia Li; Ji-Feng Li; Chun-Hu Lin; Xiu-Ming Zhong; Zhou Wang; Dai-Zhong Wang
Journal:  J Neuropathol Exp Neurol       Date:  2019-07-04       Impact factor: 3.685

8.  Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases.

Authors:  D M England; L Hochholzer; M J McCarthy
Journal:  Am J Surg Pathol       Date:  1989-08       Impact factor: 6.394

9.  Solitary fibrous tumors of soft tissue. A clinicopathologic and immunohistochemical study of 12 cases.

Authors:  S Suster; A G Nascimento; M Miettinen; J Z Sickel; C A Moran
Journal:  Am J Surg Pathol       Date:  1995-11       Impact factor: 6.394

10.  Recurrence of Solitary Fibrous Tumor/Hemangiopericytoma Could Be Predicted by Ki-67 Regardless of Its Origin.

Authors:  Yumiko Yamamoto; Yoshihiro Hayashi; Ichiro Murakami
Journal:  Acta Med Okayama       Date:  2020-08       Impact factor: 0.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.